Camilla Thim Damgaard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Camilla Thim Damgaard has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Hanne Bødtcher
Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark
1 shared publication - Helle Enggaard
Clinical Nursing Research Unit & Clinical Cancer Research Center, Aalborg University Hospital, Sdr. Skovvej 15, Aalborg, Denmark
1 shared publication - Iben Husted Nielsen
Department of Haematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
1 shared publication - Kristina Holmegaard Nørskov
Department of Haematology, Zealand University Hospital, Køge, Denmark
1 shared publication - Susanne Oksbjerg Dalton
Danish Cancer Institute, Danish Cancer Society, Copenhagen, Denmark
1 shared publication - Tine Rosenberg
Quality of life Research Center, Department of Hematology, Odense University Hospital, Odense, Denmark
1 shared publication
Latest Publications
- Open Access
- 30 October 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (11) , 1-10
Home-based treatment for patients with hematological cancer in Denmark–A national overview
Purpose: To investigate the extent and practice of home-based treatment for patients with hematologic malignancies in Denmark. Methods: This nationwide exploratory study was conducted at all Danish hematologic departments ( n = 9). Each site received an online questionnaire for the collection of data on the type of therapy administered as home-based treatment, the specific treatments with details on target populations, patient criteria, implementation status, and practice for clinical management. Results: Six types of therapy were offered as home-based treatments across the Danish hematologic departments: chemotherapy, immunoglobulin, immunotherapy, hydration therapy, antibiotics, and parenteral nutrition. In total, 17 treatments were offered, with the majority being provided to patients with multiple myeloma. Immunoglobulin and antibiotics were most often provided at home. Variations were identified regarding patient criteria for receiving home-based treatment, including personal resources and social networks, use of intravenous accesses and infusion pumps, and timing of initiation of home-based treatment. Conclusion: There is variation in the implementation of home-based treatment for patients with hematologic malignancies in Denmark, including different criteria and practices. To fully realize the benefits of home-based treatment, it is imperative to address access disparities, standardize practices, and enhance support for patients and caregivers. Continued research, collaboration, and policy development are essential to ensure that all patients have equitable access to high-quality home-based treatment options.
- 30 October 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (11) , 1-10
Open AccessHome-based treatment for patients with hematological cancer in Denmark–A national overview
Purpose: To investigate the extent and practice of home-based treatment for patients with hematologic malignancies in Denmark. Methods: This nationwide exploratory study was conducted at all Danish hematologic departments ( n = 9). Each site received an online questionnaire for the collection of data on the type of therapy administered as home-based treatment, the specific treatments with details on target populations, patient criteria, implementation status, and practice for clinical management. Results: Six types of therapy were offered as home-based treatments across the Danish hematologic departments: chemotherapy, immunoglobulin, immunotherapy, hydration therapy, antibiotics, and parenteral nutrition. In total, 17 treatments were offered, with the majority being provided to patients with multiple myeloma. Immunoglobulin and antibiotics were most often provided at home. Variations were identified regarding patient criteria for receiving home-based treatment, including personal resources and social networks, use of intravenous accesses and infusion pumps, and timing of initiation of home-based treatment. Conclusion: There is variation in the implementation of home-based treatment for patients with hematologic malignancies in Denmark, including different criteria and practices. To fully realize the benefits of home-based treatment, it is imperative to address access disparities, standardize practices, and enhance support for patients and caregivers. Continued research, collaboration, and policy development are essential to ensure that all patients have equitable access to high-quality home-based treatment options.